Tyra rolls toward pivotal bladder cancer study even as midphase data deflates stock

Tyra Biosciences has reported initial phase 2 data on dabogratinib in bladder cancer, putting the biotech on course to start a registrational study next year. But the biotech’s stock fell in premarket trading after the complete response rate fell short of the level targeted by analysts.